The global clinical trials market is anticipated to grow at a CAGR of 6-7% from 2024 to 2029. This growth is driven by the ...
As 2026 approaches, the clinical research and development landscape is evolving beyond traditional scientific innovation with ...
Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the ...